MedTrace Logo

Augmented Virtual Reality for Reducing Pain, Stress, Anxiety and Improve Self Efficacy in Adult Cancer Patients Undergoing Chemotherapy in The West Bank

NCT07152938 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-09-15

No results posted yet for this study

Summary

The main purpose of this study is to examine the effect of using AVR on pain, stress, anxiety, and SE among adult cancer patients undergoing chemotherapy in the West Bank hospitals in Palestine. The main questions it aims to answer are:

1. What is the effect of AVR therapy on pain levels score compared with routine care during chemotherapy session among cancer patients?
2. What is the effect of AVR therapy on the stress levels compared with routine care during chemotherapy session among cancer patients?
3. What is the effect of AVR therapy on the anxiety compared with routine care during chemotherapy session among cancer patients?
4. What is the effect of AVR therapy on the general SE compared with routine care during chemotherapy session among cancer patients?

The participants divided into two groups, the intervention group, which receives AVR, and the control group, which receives standard treatment. The study used a pretest and posttest design to assess the effect of AVR on the study variables (pain, stress, anxiety and self-efficacy).

Conditions

  • Cancer and Chemotherapy Related Anemia
  • Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)

Interventions

BEHAVIORAL

AVR Group (Chemotherapy + AVR)

the intervention group received AVR before they started treatment and during the session. The researcher administered the posttest questionnaire The questionnaire assessed immediately after finishing AVR. Participants informed not to discuss AVR with each other's, as the researcher explained to the participants the purpose of the study and their participation will not affect their care or treatment

Sponsors & Collaborators

  • Arab American University (Palestine)

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2023-09-30
Completion
2023-10-30

Countries

  • Palestinian Territories

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07152938 on ClinicalTrials.gov